The SHC4 antibody is designed to detect SHC4 (SHC-transforming protein 4), a member of the SHC (Src homology 2 domain-containing) adaptor protein family, which includes SHC1. SHC2. SHC3. and SHC4. These proteins function as signaling adaptors, linking activated receptor tyrosine kinases (RTKs) to downstream pathways such as RAS-MAPK and PI3K-AKT, which regulate cell proliferation, differentiation, and survival. SHC4. also known as SHC-D or RaLP (Ret oncogene-associated laminin-like protein), contains conserved phosphotyrosine-binding (PTB) and Src homology 2 (SH2) domains that enable interactions with phosphorylated tyrosine residues on activated receptors. Unlike other SHC members, SHC4 is primarily expressed in neural and melanocytic tissues and has been implicated in cancer progression, particularly melanoma. Studies suggest SHC4 overexpression correlates with tumor metastasis, drug resistance, and poor prognosis. SHC4 antibodies are essential tools for investigating its role in oncogenic signaling, tumor microenvironment interactions, and potential therapeutic targeting. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess SHC4 expression and localization in research models or clinical samples. Recent interest in SHC4 has grown due to its potential as a biomarker or target in precision oncology.